Allergic asthma is the most prevalent form of asthma. Approximately 60% of asthma patients have allergic asthma 2 and 75% of patients aged ≥12 years with moderate to severe asthma were found to have allergic asthma in a separate study. 3 For pediatric asthma patients, prevalence of allergic asthma grows to 4 out of 5. 4 For appropriate asthma patients 6 years of age and older, when you know it’s allergic asthma, think XOLAIR.

IgE, immunoglobulin E.


XOLAIR is for patients aged 6 years and older with moderate to severe persistent Allergic Asthma who are uncontrolled on inhaled corticosteroids (ICS). 1

Additional Information

  • XOLAIR is the only FDA-approved biologic drug designed to block IgE
  • Prescribed for over 250,000 patients with allergic asthma 10

Find out more about when to consider XOLAIR for Allergic Asthma.

XOLAIR for Appropriate Allergic Asthma Patients 6 Years or Older

Who Might Be Appropriate for XOLAIR?

Patients with moderate to severe asthma 1:

  • Uncontrolled on ICS
  • With sensitivity to a perennial aeroallergen (eg, dust mites, pet dander, cockroach debris)
  • Aged ≥6 years

Patients aged 6 to <12 years 1:

  • Total IgE level of ≥30 to 1300 IU/mL
  • Body weight of 44 to 330 pounds

Patients aged ≥12 years 1:

  • Total IgE level of ≥30 to 700 IU/mL
  • Body weight of 66 to 330 pounds

Dosing is based on a combination of age, IgE level, and body weight. Please see dosing tables in the full Prescribing Information. 1

To learn more about the efficacy and safety profile of XOLAIR for appropriate allergic asthma patients, view the clinical studies.

Find out more about when the National Heart, Lung, and Blood Institute (NHLBI) Guidelines recommend XOLAIR in patients 12 years and older.

XOLAIR Mechanism of Action (MOA)—Designed to Target IgE 1

The majority of cases in asthma are due to allergic inflammation 1,2

Allergic asthma is driven by IgE 28

XOLAIR Is the Only Approved Biologic Designed to Target and Block IgE 1*

  • Reduces mean serum free IgE by >96% when using recommended doses 1
  • Downregulates high-affinity IgE receptors (FcεRI) on multiple cells (eg, basophils, mast cells, and dendritic cells) 1,29
  • Prevents IgE cross-linking 6
  • Limits mast cell degranulation 6
  • Minimizes the release of mediators in the early and late phases of the allergic inflammatory cascade 1,5-7

*Based on preclinical models.

XOLAIR is a recombinant, DNA-derived, humanized IgG1κ monoclonal antibody. 1

XOLAIR is not indicated for other allergic conditions.

IgG1κ, immunoglobulin G1κ; IL, interleukin.

Learn more about IgE and the specific IgE tests that can be used to help confirm an allergic asthma diagnosis in your patients.